Short Interest in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Expands By 13.6%

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 595,300 shares, an increase of 13.6% from the December 31st total of 523,900 shares. Approximately 7.5% of the company’s shares are sold short. Based on an average trading volume of 260,300 shares, the days-to-cover ratio is presently 2.3 days.

Analyst Upgrades and Downgrades

Several research firms recently commented on CTXR. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price target on shares of Citius Pharmaceuticals in a research note on Tuesday, November 12th. D. Boral Capital restated a “buy” rating and issued a $9.00 target price on shares of Citius Pharmaceuticals in a research note on Tuesday, January 7th.

Hedge Funds Weigh In On Citius Pharmaceuticals

Several institutional investors have recently made changes to their positions in CTXR. Point72 DIFC Ltd bought a new position in Citius Pharmaceuticals in the second quarter worth approximately $29,000. XTX Topco Ltd purchased a new position in shares of Citius Pharmaceuticals in the 3rd quarter valued at $47,000. Miller Investment Management LP raised its position in shares of Citius Pharmaceuticals by 99.3% in the 3rd quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock worth $50,000 after acquiring an additional 49,640 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Citius Pharmaceuticals during the 3rd quarter worth $50,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Citius Pharmaceuticals during the second quarter valued at about $69,000. Hedge funds and other institutional investors own 16.88% of the company’s stock.

Citius Pharmaceuticals Stock Performance

NASDAQ CTXR traded down $0.05 on Monday, reaching $2.65. 12,269 shares of the stock traded hands, compared to its average volume of 109,991. Citius Pharmaceuticals has a 12 month low of $2.44 and a 12 month high of $26.75. The company has a market cap of $22.72 million, a price-to-earnings ratio of -0.44 and a beta of 1.29. The company has a fifty day moving average price of $3.33 and a 200-day moving average price of $9.91.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.